Sirio Introduces New Gummibiotic Line with Both Probiotics and Postbiotics

Sirio Pharma, a leading nutraceutical contract development and manufacturing organization (CDMO), is set to introduce its new GummiBiotics supplements at CPHI Milan. These innovative gummies are designed to enhance immune and digestive health, as well as aid in weight management and loss, through a combination of pro- and postbiotics.

The GummiBiotics Defense variant includes 500 mg of EpiCor postbiotic per serving, supplemented with zinc to bolster the immune system’s normal function. This marks the first time a gummy has incorporated EpiCor, a postbiotic that has been clinically proven to enhance both immune and gut health.

Additionally, Sirio has unveiled the GummiBiotics IBS Ease, which incorporates ADM’s ES1 postbiotic. Clinical studies have shown that ES1 can help alleviate certain symptoms of IBS-D. This gummy is further fortified with xylo-oligosaccharides, known to improve IBS-D symptoms, and calcium, which supports the normal function of digestive enzymes.

The GummiBiotics Lean product features a blend of apple cider vinegar, vitamin B6, and the DE111 probiotic, a Bacillus subtilis strain that has been shown to assist with weight management and loss. It also includes Sirio’s proprietary Apple Cider Vinegar Natuful Postbiotic.

Sara Lesina, the general manager of Sirio Europe and Americas, expressed pride in the company’s research and development prowess. “At SIRIO, we dedicate a significant portion of our earnings to R&D, with our technical and formulation teams making up 13% of our workforce—a rarity in the CDMO space,” she said. “We’re not just keeping up with market trends; we’re creating top-tier, innovative products that pave new paths for nutraceutical brands. The launch of GummiBiotics is particularly thrilling as it leverages our strong partnerships with leading ingredient suppliers and merges scientifically supported biotics with truly tasty gummies, transforming the consumer experience.”